A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Trial Profile

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Namilumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms NEXUS
  • Sponsors Takeda
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jan 2017 This trial has been completed in Czech Republic(End date:2016-11-16) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top